Skip to main content
Fig. 2 | Breast Cancer Research

Fig. 2

From: A phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic HER2-negative breast cancer

Fig. 2

A Pharmacokinetics in ascites versus plasma in BROR-16. B Pharmacokinetics in pleural fluid versus plasma in BROR-17. Zilovertamab concentration (mcg/mL) is indicated on the y axis, and time (weeks) is indicated on the x axis. Arrows indicate days of infusion of zilovertamab. BROR-02 plasma levels are included as representative of the mean concentration of zilovertamab of 58 mcg/ml among 6 patients analyzed at 8 weeks (see Fig. 1)

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us